FMP
Silverback Therapeutics, Inc.
SBTX
NASDAQ
Inactive Equity
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
5.87 USD
0.06 (1.02%)
About
ceo
Dr. Peter A. Thompson M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.silverbacktx.com
exchange
NASDAQ
Description
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
CIK
0001671858
ISIN
US82835W1080
CUSIP
82835W108
Address
500 Fairview Avenue North
Phone
206 456 2900
Country
US
Employee
90
IPO Date
Dec 3, 2020
Key Executives
